Earlier this month, the Federal Circuit decided a subject matter eligibility case closely watched in the pharmaceutical ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.5, expectations were $1.38. Operator: Good afternoon. And welcome to the ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), ...

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a ...

Sarepta Therapeutics Inc (SRPT) reports a 75% increase in quarterly revenues and outlines ambitious growth plans for 2025.

Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call.

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced in Q4 CY2024, with sales up 65.9% year on year to $658.4 million ...

CAMBRIDGE, Mass. - Sarepta Therapeutics (NASDAQ: SRPT) reported fourth quarter earnings that beat analyst expectations, but the stock fell 4.6% as investors focused on rising expenses.

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported fourth-quarter profit of $159 million. On a per-share basis, the Cambridge, Massachusetts-based ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...